Juneko Grilley-Olson, MD, Duke University, Durham, NC, discusses the promising results of the Phase II Alliance A091902 (NCT04339738) trial investigating the combination of cabozantinib and nivolumab for patients with locally advanced/metastatic angiosarcoma who had previously received taxane chemotherapy. The study enrolled patients who were not restricted on the number of prior lines but had not received prior anti-VEGF and immunotherapies. The combination therapy showed significant antitumor activity, with an objective response rate (ORR) of 62%, including responses in both cutaneous and noncutaneous disease subtypes. The treatment was well-tolerated without new safety concerns. The study highlights the potential of the cabozantinib and nivolumab combination in angiosarcoma subtypes, offering a new therapeutic option for patients with angiosarcoma pretreated with taxane. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL